Skip to main content
Premium Trial:

Request an Annual Quote

Singlera Raises $20M in Series A Round

NEW YORK (GenomeWeb) – Genetic testing startup Singlera Genomics announced today that it has raised $20 million in a Series A financing round.

The round was led by Lilly Asia Ventures, and included Green Pine Capital Partners and CDBI Partners, among other investors.

Singela was founded in mid-2014 to commercialize noninvasive prenatal testing technologies developed at Johns Hopkins and the University of California, San Diego. The company has also been working on developing genomic sequencing tests for cancer and other diseases, and recently formed a partnership with Fudan University's Taizhou Health Science Institute to identify biomarkers of early-stage cancer.

The firm said it would use the proceeds of the financing round to facilitate the development and commercialization of its genetic tests, as well as to expand its R&D operations and efforts around new product lines for tumor diagnosis and personalized treatment.

"Singlera's noninvasive genomic sequencing diagnostic technologies could significantly enhance the accuracy of tumor diagnosis and provide powerful guidance for … new treatments," Chairman and Co-founder Yuan Gao said in a statement. "This new funding is a strong vote of confidence in our technologies, scientific research and commercial operations from a group of highly respected healthcare investors."

The Scan

Booster for Kids

The US Food and Drug Administration has authorized a booster dose of Pfizer-BioNTech's SARS-CoV-2 vaccine for 5-to-11-year olds, the Washington Post reports.

Novavax Anticipates Authorization

Novavax expects to receive US Food and Drug Administration authorization for vaccine soon, according to CNBC.

Some Old Microbes Indeed

Vice reports that researchers may have uncovered 830-million-year-old microbes.

PNAS Papers on Meiotic Crossover, RNA Targeting, SNAT7 mTORC1 Regulation

In PNAS this week: meiotic crossover formation in C. elegans, approach to identify small molecules affecting RNA activity, and more.